Company / PP&E (Net)
Terns Pharmaceuticals, Inc. PP&E (Net) History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$222.0K
FY2024
5-year range
$222.0K / $1.2M
FY2020-FY2024
Trend
-56.1%
vs FY2023
Sector context
#180 of 197
Health Care
What the data says
Among 197 Health Care companies, Terns Pharmaceuticals, Inc. is in the bottom 9% for pp&e (net). PP&E (Net) has declined for 4 consecutive years, from $1M in FY2020 to $222,000 in FY2024.
Based on SEC 10-K filings.
$222,000 in FY2024 with a 3-year CAGR of -40.4%.
Declined from $757,000 to $222,000 over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -40.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 197This company $222.0K Sector average $773.5M
▼
-100.0% below sector average
Key checks
Key Insights
- Terns Pharmaceuticals, Inc.'s pp&e (net) has declined for 4 consecutive years.
- 3-year CAGR of -40.4%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 56.1% year-over-year.
- Ranks #180 out of 197 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $222.0K | -56.1% |
| FY2023 | $506.0K | -33.2% |
| FY2022 | $757.0K | -27.6% |
| FY2021 | $1.0M | -11.0% |
| FY2020 | $1.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026